Aclaris Therapeutics(股票代码:ACRS)已正式启动其创新双特异性抗体ATI-052针对特应性皮炎(AD)的1B期概念验证临床试验。该试验旨在评估ATI-052在患者中的初步疗效与安全性,标志着公司在该治疗领域的重要进展。
Aclaris Therapeutics(股票代码:ACRS)已正式启动其创新双特异性抗体ATI-052针对特应性皮炎(AD)的1B期概念验证临床试验。该试验旨在评估ATI-052在患者中的初步疗效与安全性,标志着公司在该治疗领域的重要进展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.